Health officials in the US have granted full approval to a landmark Alzheimer’s drug which has been shown to slow the cognitive decline caused by this horrific form of dementia.
The Food and Drug Administration (FDA) approval has cleared the way for Medicare and other insurance plans to begin covering treatment using Leqembi.
The horrendous disease, which can see patients forgetting their dearest family members, is on the rise in the US and abroad.
